Kevin Dunworth

Founder / CEO

Kevin Dunworth, Founder of Celling Technologies^®, has spent more than 26 years in the orthopedic industry and brings a wealth of expertise in all aspects of the business. Dunworth has run medical companies in the Middle East, Eastern and Western Europe, and the United States.

He excelled in various executive positions before founding VCD Medical, in Austin, Texas.
For the past eight years, Dunworth has successfully built a world-class distribution business, which provides a variety of orthopedic and biologic products.

Dunworth's leadership roles within the orthopedic industry have included, Director of Emerging Markets and Director of European Sales for Smith & Nephew; Director of International Sales, Vice President of Worldwide Sales and Vice President for FlouroScan International and Vice President of Sales for TransLeasing and Vice President for TransLeasing GE.

Steve Melchiode

President
Steve Melchiode has extensive experience guiding businesses from start-up to profitability. After earning an undergraduate marketing degree followed by a law degree, Melchiode joined a start-up technology firm in Silicon Valley as the West Coast business development director. Melchiode's ability to build and lead successful companies, combined with his experience in medical device sales, provides him with the vision and expertise to lead the Celling Technologies^® team. He brings a wide range of experience in sales, business development, marketing, finance, legal and operations management.

Melchiode began his medical device career as a sales representative with VCD Medical, learning the spinal implant industry selling Depuy Spine. After two years spent growing several new territories, Melchiode established himself in a leadership role as sales manager and by running operations for the State of Texas. For the past two years, he has worked with Kevin Dunworth to take the Celling Technologies^® model from concept to market, working on business, product and partnership development as well as marketing and operations.

Michael Gluk

Chief Operating Officer, Chief Financial Officer
Michael Gluk joined Celling Technologies^® in July 2009 as Chief Operating Officer. Prior to joining the company, Michael served as CFO of ArthroCare, a $300 million dollar revenue medical device company where he led the finance, human resource and information technology functions. From 1985 through 2004 Michael worked at General Motors Corporation in a variety of financial and business development positions, including general director of financial planning, controller of GM do Brasil and director of business development for eGM.

Mr. Gluk holds a Masters of Business Administration degree from Indiana University and a Bachelor of Science degree in Business Administration from Miami University of Ohio.

Jim Poser, PhD

VP of Regenerative Medicine

Jim Poser joined Celling Technologies^® in March 2009 as Vice President of Regenerative Medicine. Poser began his industrial career over 28 years ago as a research scientist developing bone diagnostics and orthobiologics for skeletal repair. Dr. Poser has held executive positions of increasing responsibility with Sulzer Orthopedics, Osteotech, Orquest, Stryker Orthopaedics and IsoTis Orthobiologics among others.

Poser has been responsible for the development of many successful synthetic and allograft-based bone graft materials, is the inventor on nine patents and author on over 40 peer-reviewed publications. For the past several years Dr. Poser has directed his attention to the development of cell-based therapies for tissue regeneration.

Dr. Poser holds a Doctorate in Chemistry from University of California San Diego and a Bachelor of Science degree Biochemistry and Molecular Biology from University of California Santa Barbara.

Kevin Were

VP of Business Development

Kevin Were joined Celling Technologies^® in May 2009 as Director of Business Development. Mr. Were has over 20 years experience in the medical device and osteobiologic market and provides proven leadership to the sales and business development teams. Prior to joining the company, Mr. Were held numerous executive positions including management and business development positions at Integra Orthobiologics, IsoTis Orthobiologics, GenSci, Acromed and most recently Vice President of Sales at Spine Matrix.

Mr. Were is responsible for expanding the company's presence both regionally and nationally by growing direct sales, identifying Institutes of Regenerative Medicine and building a distribution network. Mr. Were will work closely with the Institutes of Regenerative Medicine sites by implementing strategic plans to research and develop adult stem cell technologies and lead collaboration for all partners involved.

Mr. Were earned a B.S. In Electrical Engineering from the University of New South Wales in Sydney Australia.

Ted Sand, PhD

Vice President of Cellular Therapies

Theodore Sand joined Celling Technologies^® as Vice President of Cellular Therapies in January 2011. Prior to that Dr. Sand had been a consultant to the company since January 2010.

Dr. Sand has worked in various companies involved in human diagnostics, including point-of-care, rapid diagnostic devices as well as clinical microbiology laboratory diagnostic technology. Most recently, he developed the technology platform for obtaining progenitor and stem cells from a patient’s adipose tissue in use at Vet-Stem, Inc., which provides autologous adipose-derived cell therapy to treat a variety of orthopedic pathologies in the veterinary world, including osteoarthritis, tendon and ligament injuries.

Dr. Sand received his B.S. in Microbiology and his Ph.D. in Biochemistry from the University of Minnesota, Twin Cities. He was a post doctoral fellow at Scripps Clinic and Research Foundation in La Jolla, CA. He has more than 9 patents and patent applications covering cell-based regenerative medicine, biosensor technology and diagnostics.